Radar · Biopharma Outsourcing in Massachusetts
Best Biopharma Outsourcing Companies in Massachusetts, United States
The 227 best Biopharma Outsourcing companies in Massachusetts, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Biocytogen.
By Rohit KhannaTrends & Stories
227companies tracked
$2.4Bdisclosed funding
0unicorns
63have raised
FLIAR INTELLIGENCE · BIOPHARMA OUTSOURCING × MASSACHUSETTS
Our analysis of 50 Biopharma Outsourcing companies
$6.3b in tracked funding; 77% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
50companies analysed
77%cloud-native stacks
2025funding peak (by rounds)
2018median founding year
45median Fliar Index™
344kcombined LinkedIn audience
60%of audience held by top 3
5companies hiring publicly (12 mo)
Ranked: Best Biopharma Outsourcing companies in Massachusetts
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Biocytogen Provider of integrated solutions for next-generation antibody drug development | $301M | 59 mo ago | Public | 85 | Yuelei Shen Founder & CEO | PHPBootstrapWisepops+14 | 2 patents Precise genome editing knock‑in technology for targeted DNA insertion | — |
| 2 | Ventus Therapeutics Develops small‑molecule therapeutics for autoimmune and auto‑inflammatory diseases treatment | $300M | 52 mo ago | Series C | 76 | — | — | 152 patents Small‑molecule inhibitors of NLRP3 inflammasome and related caspase pathways | — |
| 3 | New England Research Institutes CRO delivering customized research and clinical trial solutions | $283M | 111 mo ago | Acquired | 9 | — | — | — | — |
| 4 | Aiolos Bio Biotech company focused on developing innovative therapies for respiratory diseases and immune conditions | $245M | 31 mo ago | Acquired | — | Elizabeth Holt Founder and VP | — | — | — |
| 5 | Blue Rock Therapeutics Stem cell therapies for cardiovascular and neurological diseases | $225M | 114 mo ago | Acquired | 138 | — | WordPressApple iCloud MailMySQL+22 | — | — |
| 6 | Superluminal Medicines Generative biological and chemical company focused on drug discovery 57Funding top 21%Talent top 38%Market bottom 44%Partners bottom 35% All 6 signals ▾Fundingtop 21% Talenttop 38% Marketbottom 44% Partnersbottom 35% Globalbottom 29% Newsbottom 15% Funding: Raised $153M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 57/100 | $153M | 10 mo ago | Series A | — | Ajay Yekkirala Co-Founder | — | — | — |
| 7 | Alloy Therapeutics Provider of drug discovery services 60Funding top 20%News top 32%Growth top 37%Tech top 39% All 8 signals ▾Fundingtop 20% Newstop 32% Growthtop 37% Techtop 39% Talentbottom 49% Marketbottom 38% Moatbottom 38% Globalbottom 37% Funding: Raised $117M across 3 rounds · 3 rounds over 5 yrs (0.6/yr) News: 3 BI events in 12 mo (of 14 tracked, 5 types) · Top themes: Funding, Capital raise, M&A rank vs industry peers · Fliar Intelligence Index 60/100 | $117M | 2 mo ago | Series E | 130 | Errik Anderson CEO | WordPressApple iCloud MailGoogle Workspace+32 | — | 1 job opening · 1 partnership |
| 8 | Hydra Biosciences Develops ion-channel based drugs for diabetic neuropathy, allergic asthma and pulmonary diseases | $112M | 135 mo ago | Series E | 12 | — | — | 397 patents Small-molecule TRPC6/TRPC5 ion channel inhibitors for therapeutic modulation. | — |
| 9 | Matchpoint Therapeutics Provider of small molecular medicine development and analytics services | $100M | 44 mo ago | Series A | 27 27 → 32 (+19%) | Tinghu Zhang Co-Founder | — | — | — |
| 10 | Arranta Bio Developer of therapeutics for microbiome based diseases | $82M | 79 mo ago | Acquired | 200 | — | — | — | 1 partnership · 1 expansion |
| 11 | Hyku Biosciences Covalent medicines platform for expanding the boundaries of drug discovery 57Funding top 33%Talent bottom 49%Global bottom 38%News bottom 18% All 4 signals ▾Fundingtop 33% Talentbottom 49% Globalbottom 38% Newsbottom 18% Funding: Raised $56.0M across 2 rounds · 2 rounds over 3 yrs (0.7/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 57/100 | $56M | 6 mo ago | Seed | — | Kleem Chaudhary President & Chief Executive Officer | — | — | — |
| 12 | Manifold Bio Developer of tissue-targeted therapeutics using in vivo screening and AI design 29Funding top 34%Talent top 45%Moat bottom 38%Global bottom 37% All 5 signals ▾Fundingtop 34% Talenttop 45% Moatbottom 38% Globalbottom 37% Marketbottom 26% Funding: Raised $45.4M across 3 rounds · 3 rounds over 6 yrs (0.5/yr) Talent: 3 named leaders on record · 3 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 29/100 | $45M | 19 mo ago | Series A | 22 | Gleb Kuznetsov Co-Founder & CEO | — | — | — |
| 13 | Affyimmune Therapeutics Limited information available | $38M | 56 mo ago | Series A | 26 | — | — | — | — |
| 14 | Peplib Provider of peptide drug discovery and development services for global pharmaceutical industries | $34M | 61 mo ago | Series A | 7 | Li Sean Co-Founder | — | — | 4 job openings |
| 15 | Aliada Therapeutics Provider of drug research & development services for multiple therapeutic areas | $33M | 59 mo ago | Acquired | 18 | — | — | — | — |
| 16 | Biomere CRO specializing in animal model development | $21M | 113 mo ago | Funding Raised | 128 | — | WordPressMySQLPHP+19 | — | 1 partnership |
| 17 | Oryon Developer of autologous neuron replacement medicines for neurodegenerative disorders 50Talent top 28%Funding top 45%Innovation top 49%Patents top 49% All 5 signals ▾Talenttop 28% Fundingtop 45% Innovationtop 49% Patentstop 49% Globalbottom 42% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $21.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 50/100 | $21M | 2 mo ago | Series A | — | Ole Isacson Co-Founder | — | 20 patents Electroluminescent lighting and flexible EL display technologies with nano‑engineered phosphor layers | — |
| 18 | Meadowhawk Biolabs CRO focused on providing of drug discovery, pharmacology, and bioanalytical services | $20M | 23 mo ago | Series A | 35 | — | WordPressApple iCloud MailMicrosoft 365+25 | — | — |
| 19 | Xsphera Biosciences Developer of tumor preservation platform | $20M | 48 mo ago | Seed | 23 | Steve Remondi Co-Founder & CEO | — | — | 1 launch |
| 20 | Berkshire Sterile Manufacturing Provider of sterile filling and lyophilization services for clinical and small scale requirements | $19M | 36 mo ago | Acquired | 188 | Andrea Wagner Co-Founder | Cart FunctionalityWordPressUnbounce+26 | — | — |
| 21 | Dash Bio Provider of automated bioanalysis platform for accelerated clinical drug development 40Talent top 38%Funding top 39%Global bottom 33% All 3 signals ▾Talenttop 38% Fundingtop 39% Globalbottom 33% Talent: 2 named leaders on record · 2 C-suite/founder profiles curated Funding: Raised $17.5M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 40/100 | $18M | 12 mo ago | Series A | — | Ander Tallett Co-Founder & COO | — | — | — |
| 22 | Curavit Contract research organization that offers a complete suite of CRO services for decentralized clinical trials | $16M | 43 mo ago | Series A | 26 | — | WordPressMySQLPHP+29 | — | — |
| 23 | DoubleRainbow Biosciences Developer of sustainable therapeutics and nutraceuticals using natural product manufacturing | $15M | 67 mo ago | Series B | 15 | Tian Xu Co-Founder | — | — | — |
| 24 | TissueVision Innovating whole tissue imaging and analysis solutions for life-saving therapies 22Patents top 40%Funding top 43%Moat top 45%Innovation top 48% All 7 signals ▾Patentstop 40% Fundingtop 43% Moattop 45% Innovationtop 48% Techbottom 42% Globalbottom 37% Marketbottom 26% Patents: 41 patents matched (strict assignee match) · 9 filings since 2022 vs 15 in 2017-21 Funding: Raised $13.4M across 15 rounds · 15 rounds over 17 yrs (0.9/yr) rank vs industry peers · Fliar Intelligence Index 22/100 | $13M | 12 mo ago | Funding Raised | 17 | — | — | 41 patents Automated digital pathology: tissue section handling, indexing, multiplex imaging, and serial staining. | — |
| 25 | Biosim Provider of contract based drug discovery services | $12M | 28 mo ago | Series B | 34 | — | — | — | — |
| 26 | Lytica Therapeutics Developer of therapeutic drugs | $12M | 15 mo ago | Series A | 10 | Jim LaTorre CEO | — | — | — |
| 27 | ZWI Therapeutics Provider of recruitment services | $10M | 28 mo ago | Series A | 3 | — | — | — | — |
| 28 | Horsepower Tech Manufacturer of rehabilitative medical devices for horses | $9M | 73 mo ago | Series A | 3 | Chandra Mouli Ramani CEO | — | — | — |
| 29 | Sunstone Provider of clinical trial services for patient recruitment services | $8M | 29 mo ago | Series A | 28 | — | WordPressApple iCloud MailMySQL+27 | 79 patents Oil and gas drilling pipe spline connections and integrated downhole electrical wiring. | 1 job opening |
| 30 | Continuus Pharma Innovative pharmaceutical manufacturing solutions using integrated continuous manufacturing (ICM) | $8M | 81 mo ago | Series B | 47 | Bayan Takizawa Co-Founder | WordPressMySQLPHP+20 | — | — |
| 31 | Kano Therapeutics Developer of circular single-stranded DNA for targeted gene-length DNA correction | $7M | 25 mo ago | Seed | 9 | Mark Bathe Co-Founder | WordPressMySQLPHP+15 | — | — |
| 32 | Enquyst Technologies Inc Bioprocessing company that is developing biomanufacturing technology solutions and biological drug production | $6M | 12 mo ago | Series A | 8 | — | — | — | — |
| 33 | Leadart Biotechnologies Provider of drug target discovery platform and probe library | $6M | 41 mo ago | Seed | 60 | Yufeng Zhao Co-Founder | — | — | — |
| 34 | Lifordi Biotechnology company developing treatments for autoimmune and inflammatory disorders using antibody-drug… 45Funding top 45%Talent bottom 49%Global bottom 36% All 3 signals ▾Fundingtop 45% Talentbottom 49% Globalbottom 36% Funding: Raised $5.9M across 2 rounds · 2 rounds over 3 yrs (0.7/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 45/100 | $6M | 6 mo ago | Seed | — | Arthur Tzianabos CEO | — | — | — |
| 35 | Eulysis Provider of diabetes management and lifestyle modification services | $5M | 132 mo ago | Series A | 3 | — | — | — | — |
| 36 | Protein Dynamic Solutions Transforming protein analytics for better biotherapeutics, enhancing regulatory compliance 42Patents top 25%Innovation top 26%Talent top 28%Moat top 32% All 7 signals ▾Patentstop 25% Innovationtop 26% Talenttop 28% Moattop 32% Fundingtop 48% Globalbottom 35% Marketbottom 14% Patents: 55 patents matched (strict assignee match) · 34 filings since 2022 vs 21 in 2017-21 Innovation: 55 patents (top 29% of patent-holders) · 34 filings since 2022 vs 21 in 2017-21 rank vs industry peers · Fliar Intelligence Index 42/100 | $4M | 10 mo ago | Seed | 9 | William Lockwood-Benet Co-Founder | — | 55 patents Analytical methods for protein deamidation, immunogenicity, purity, and epitope mapping | 1 launch |
| 37 | BioAssets Development Corporation Producer of biologic drugs to treat the cause of pain in spinal disorders | $4M | 201 mo ago | Deadpooled | — | Frank Baldino Chairman & CEO | — | — | — |
| 38 | Prestige Scientific Provider of diversified consulting services for biopharma sector | $3M | 14 mo ago | Funding Raised | 73 | Dexter Head CEO | WebflowSplidejQuery+8 | — | 3 job openings |
| 39 | Sunflower Therapeutics Provider of drug development & research services for multiple therapeutic areas | $3M | 9 mo ago | Series A | 10 | — | — | — | 1 launch |
| 40 | Javelin Biotech CRO focused on providing drug discovery and preclinical study services | $3M | 33 mo ago | Funding Raised | 11 11 → 7 (-36%) | Kevin O'Handley Co-Founder and COO | Cart FunctionalitySquarespace CommerceSquarespace+12 | — | — |
| 41 | CuriRx Pharmaceutical CRDMO providing innovative drug development solutions and analytical services | $2M | 47 mo ago | Seed | 29 | Indu Javeri President & CEO | — | 17 patents Enteric drug delivery formulations and liposome-based pharmaceutical preparation | 1 job opening |
| 42 | MedPanel Global healthcare market research partner providing insights for biopharma and medtech | $2M | 137 mo ago | Acquired | 30 | Janet Bernard CEO & President | — | — | — |
| 43 | MedChem Partners Chemistry support for early and mid-stage drug discovery programs | $2M | 16 mo ago | Funding Raised | — | Steven Riesinger CEO and Co-Founder | — | — | — |
| 44 | Cytel Provider of data analysis and statistical solutions for the life sciences industry | $2M | 103 mo ago | Acquired | 509 | Cyrus Mehta Co-Founder & President | WordPressApple iCloud MailMicrosoft 365+31 | 43 patents Clinical trial design and analytics platform integrating systematic literature review | — |
| 45 | Veristat Clinical research organization accelerating complex therapies through strategic planning and execution | $1M | 54 mo ago | Acquired | 207 207 → 494 (+139%) | Patrick Flanagan CEO & Chairman | HubSpot CMS HubSalesforceMaterial Design Lite+23 | — | — |
| 46 | Rubix LS Provider of data analytics services | $1M | 64 mo ago | Seed | 16 | Reginald Swift Founder & CEO | — | — | 1 launch |
| 47 | Abveris Rapid mAb Discovery Specialists | $1M | 80 mo ago | Acquired | 45 | Garren Hilow Co-Founder & CEO | — | — | — |
| 48 | IOTA Pharma Offering fragment-based drug discovery products and services | $906K | 113 mo ago | Deadpooled | 3 | — | — | — | — |
| 49 | Pearl Bio Developer of biomaterial platform using synthetic biology for diverse chemistry applications | $844K | 24 mo ago | Funding Raised | 9 | Amy Cayne Schwartz Co-Founder | — | — | — |
| 50 | Unravel Biosciences CRO offering early stage clinical development of drugs | $500K | 58 mo ago | Seed | 9 | — | — | — | — |
Top 12 Biopharma Outsourcing companies in Massachusetts
#1
Series E · Lexington, Massachusetts · founded 2017 · 130 employees$117Mraised▾
Series E · Lexington, Massachusetts · founded 2017 · 130 employees
Provider of drug discovery services
Fliar Intelligence Index™ 60how this company ranks against its industry peers
Funding
top 20%News
top 32%Growth
top 37%Tech
top 39%Talent
bottom 49%Market
bottom 38%Funding: Raised $117M across 3 rounds · 3 rounds over 5 yrs (0.6/yr) · Last round Series E (Mar 2026)
News: 3 BI events in 12 mo (of 14 tracked, 5 types) · Top themes: Funding, Capital raise, M&A
Growth: 1 acquisition/expansion move in 24 mo · Fresh capital in last 24 mo
Audience (LinkedIn): 26k LinkedIn followers — 7.6% of this cohort's audience
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: Director, Partnerships Office
Activity (LinkedIn): 1 partnerships (incl. Voro Therapeutics) announced in 12 mo
Funding rounds
- Mar 2026Series E$40M
- Oct 2022Series D$42M
- Apr 2021Series C$75M
Founders & team
Investors
8VC, Presight Capital, Mubadala, Alexandria, Founders Fund, Ulysses Diversified Holdings
Tech stack
Apple Icloud MailCloudflareCloudflare Bot ManagementCookiebotCore-JsDocusign
#2
Series A · Belmont, Massachusetts · founded 2020$21Mraised▾
Series A · Belmont, Massachusetts · founded 2020
Developer of autologous neuron replacement medicines for neurodegenerative disorders. The company focuses on developing medicines to replace lost neurons. It aims to restore function for Parkinson’s disease and other neurodegenerative disorders.
Fliar Intelligence Index™ 50how this company ranks against its industry peers
Talent
top 28%Funding
top 45%Innovation
top 49%Patents
top 49%Global
bottom 42%Talent: 3 named leaders on record · 3 C-suite/founder profiles curated
Funding: Raised $21.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Series A (Mar 2026)
Innovation: 20 patents (top 51% of patent-holders)
Funding rounds
- Mar 2026Grant (prize money)—
- Mar 2026Series A$21M
Founders & team
Investors
Byers Capital, Neuro VC
#3
Seed · Lexington, Massachusetts · founded 2023$56Mraised▾
Seed · Lexington, Massachusetts · founded 2023
It has launched with $56 million in funding to advance its covalent medicines platform, which targets histidine, tyrosine, and lysine binding pockets in disease-causing proteins. The company aims to expand the boundaries of drug discovery with its innovative covalent platform.
Fliar Intelligence Index™ 57how this company ranks against its industry peers
Funding
top 33%Talent
bottom 49%Global
bottom 38%News
bottom 18%Funding: Raised $56.0M across 2 rounds · 2 rounds over 3 yrs (0.7/yr) · Last round Seed (Dec 2025)
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Global: Investors from 3 countries beyond United States
Funding rounds
- Dec 2025Seed$6.6M
- Sep 2023Seed$56M
Founders & team
Investors
RA Capital Management, Droia Ventures, Novartis Venture Fund, The Mark Foundation, KB Investment, Eisai Innovation
#4
Series A · Boston, Massachusetts · founded 2022$153Mraised▾
Series A · Boston, Massachusetts · founded 2022
Superluminal Medicines Inc. is a biotechnology research company based in Boston, Massachusetts. They specialize in generative biological and chemical solutions for drug discovery programs. The company recently launched with a $33 million seed round to fuel its drug discovery engine and pipeline of small molecule therapeutics.
Fliar Intelligence Index™ 57how this company ranks against its industry peers
Funding
top 21%Talent
top 38%Market
bottom 44%Partners
bottom 35%Global
bottom 29%News
bottom 15%Funding: Raised $153M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) · Last round Series A (Aug 2025)
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Market: 1 contract event in 12 mo
Audience (LinkedIn): 5k LinkedIn followers
Activity (LinkedIn): 1 partnerships · 1 awards (incl. Eli Lilly & Company) announced in 12 mo
Funding rounds
- Aug 2025Series A$5M
- Aug 2024Series A$120M
- Aug 2023Seed$33M
Founders & team
Investors
RA Capital Management, Nvidia, Insight Partners, Gaingels, Catalio Capital Management, Lilly
#5
Seed · Boston, Massachusetts · founded 2023$5.9Mraised▾
Seed · Boston, Massachusetts · founded 2023
Lifordi is a biotechnology company that develops treatments for autoimmune and inflammatory disorders using antibody-drug conjugates. They have experienced leadership in drug development, immunology, and inflammatory disorders. Lifordi Immunotherapeutics is led by CEO Arthur Tzianabos.
Fliar Intelligence Index™ 45how this company ranks against its industry peers
Funding
top 45%Talent
bottom 49%Global
bottom 36%Funding: Raised $5.9M across 2 rounds · 2 rounds over 3 yrs (0.7/yr) · Last round Seed (Nov 2025)
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Global: Investors from 1 country beyond United States
Funding rounds
- Nov 2025Seed—
- Sep 2025Grant (prize money)$3M
- Jun 2023Grant (prize money)$3M
Founders & team
Investors
HHS, Sanofi Ventures, Arch Venture Partners, 5AM Ventures, Atlas Venture
#6
Funding Raised · Somerville, Massachusetts · founded 2005 · 17 employees$13.4Mraised▾
Funding Raised · Somerville, Massachusetts · founded 2005 · 17 employees
Innovating whole tissue imaging and analysis solutions for life-saving therapies. The company is a life sciences imaging solutions provider, specializing in high-throughput 3D histology and whole tissue studies. They offer services, including study design, imaging, data analysis, and custom assay development. Their technology supports research in areas like Alzheimer's disease, brain mapping, biodistribution, tumor imaging, and liver fibrosis. They utilize platforms to produce high-fidelity multi-color images of whole organs and tissues, enabling quantitative analysis. They provide contract research services, assisting researchers and companies in developing new therapeutics for diseases. Their expertise lies in tissue imaging and analysis, offering both standard and custom data pipelines for processing large data volumes. They work with fixed tissues, providing imaging and processing through standard assays, and also develop custom assays, handling entire studies from tissue labeling through image analysis and final report.
Fliar Intelligence Index™ 22how this company ranks against its industry peers
Patents
top 40%Funding
top 43%Moat
top 45%Innovation
top 48%Tech
bottom 42%Global
bottom 37%Patents: 41 patents matched (strict assignee match) · 9 filings since 2022 vs 15 in 2017-21 · Latest publication 2026
Funding: Raised $13.4M across 15 rounds · 15 rounds over 17 yrs (0.9/yr) · Last round Grant (prize money) (May 2025)
Moat: Editorial + unicorn rating 1/10 · IP moat: 41 patents
Audience (LinkedIn): 2k LinkedIn followers
Funding rounds
- May 2025Grant (prize money)$1.3M
- Aug 2023Grant (prize money)$2.5M
- Sep 2022Grant (prize money)$353.8K
- Sep 2021Grant (prize money)$478.8K
Investors
NIH SBIR/STTR, HHS
Tech stack
WixReactGoogle CloudPolyfillLodashPriority Hints
#7
Series A · Boston, Massachusetts · founded 2024$17.5Mraised▾
Series A · Boston, Massachusetts · founded 2024
Provider of automated bioanalysis platform for accelerated clinical drug development. It leverages AI and robotics to deliver high-quality assays with faster turnaround times for clinical trials and GLP studies. The company automates critical steps in bioanalysis, reducing costs and time to market. It focuses on clinical bioanalysis, specifically the testing of samples from clinical trial subjects. The platform integrates quality, automation, and regulatory compliance to enhance customer experience and outcomes.
Fliar Intelligence Index™ 40how this company ranks against its industry peers
Talent
top 38%Funding
top 39%Global
bottom 33%Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Funding: Raised $17.5M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) · Last round Series A (Jun 2025)
Global: Single-market focus (United States)
Audience (LinkedIn): 6k LinkedIn followers
Funding rounds
- Jun 2025Series A$11M
- Oct 2024Seed$6.5M
Founders & team
Investors
Freestyle, Swift Ventures, Life Extension Ventures, The Aligned Fund, Cybernetix Ventures, Drive Capital
#8
Series A · Massachusetts · founded 2018 · 22 employees$45.4Mraised▾
Series A · Massachusetts · founded 2018 · 22 employees
Developer of tissue-targeted therapeutics using in vivo screening and AI design. The company combines protein design with testing in living systems to sculpt biologics' properties. It has invented molecular tracking technologies to expand in vivo measurement of biologics. The company designs proteins for function and specificity, translating designs into biologics through synthesis and display. It is building a predictive model of living systems to map biomolecule behavior.
Fliar Intelligence Index™ 29how this company ranks against its industry peers
Funding
top 34%Talent
top 45%Moat
bottom 38%Global
bottom 37%Market
bottom 26%Funding: Raised $45.4M across 3 rounds · 3 rounds over 6 yrs (0.5/yr) · Last round Series A (Nov 2024)
Talent: 3 named leaders on record · 3 C-suite/founder profiles curated · 1 leadership moves in 12 mo
Moat: Editorial + unicorn rating 1/10 · 9 curated direct competitors tracked
Audience (LinkedIn): 12k LinkedIn followers — 3.4% of this cohort's audience
Funding rounds
- Nov 2024Series A$32.8M
- Jun 2022Series A$40M
- Aug 2020Seed$5.4M
Founders & team
Investors
Triatomic, Future Perfect Ventures, Horizons Ventures, Tencent, Fifty Years, FAST
#9
Seed · Wakefield, Massachusetts · founded 2015 · 9 employees$4.1Mraised▾
Seed · Wakefield, Massachusetts · founded 2015 · 9 employees
Transforming protein analytics for better biotherapeutics, enhancing regulatory compliance. The company specializes in advanced protein characterization solutions, enabling biopharmaceutical companies to accelerate drug development and reduce costs. Their ProteinMentor platform facilitates Critical Quality Attribute analysis, comparability studies, and release testing. The technology supports biologics and biosimilars development by providing crucial molecular dynamic information and higher-order structure characterization. Application modules offer simplified workflows for sample analysis, aiding in the determination of aggregation, stability, and charge variants. The platform is 21 CFR Part 11 compliant, ensuring data integrity for biotherapeutic testing. They offer expertise in protein forensics, aggregation analysis, and stability assessments. The company's solutions cater to drug substance and drug product evaluations, bacterial detection, and endotoxin analysis. They are focused on scientific excellence and innovation to enable better biotherapeutics for patients worldwide. This is a B2B, SaaS, software, analytics, and biopharmaceutical solution.
Fliar Intelligence Index™ 42how this company ranks against its industry peers
Patents
top 25%Innovation
top 26%Talent
top 28%Moat
top 32%Funding
top 48%Global
bottom 35%Patents: 55 patents matched (strict assignee match) · 34 filings since 2022 vs 21 in 2017-21 · Latest publication 2026
Innovation: 55 patents (top 29% of patent-holders) · 34 filings since 2022 vs 21 in 2017-21
Talent: Analyst team rating 5/5 · 2 named leaders on record
Audience (LinkedIn): 334 LinkedIn followers
Activity (LinkedIn): 1 product launches announced in 12 mo
Funding rounds
- Aug 2025Seed$1.8M
- Jan 2020Conventional Debt—
- Jan 2020Seed$610K
- Jun 2019Seed$1M
Founders & team
Investors
America’s Seed Fund
#10
Series A · Hingham, Massachusetts · founded 2018 · 10 employees$2.6Mraised▾
Series A · Hingham, Massachusetts · founded 2018 · 10 employees
Provider of drug development & research services for multiple therapeutic areas
LinkedIn Pulse recent public activity · Jul 2026
Audience: 3k LinkedIn followers
Activity: 1 product launches announced in 12 mo
Funding rounds
- Sep 2025Grant (prize money)$2.4M
- Aug 2025Grant (prize money)$306.3K
- Dec 2024Series A$3M
- May 2024Series A$2M
Investors
SK bioscience, Clear Current Capital, NIAID, HHS, Roivant Social Ventures
#11
Series A · Cambridge, Massachusetts · founded 2019 · 10 employees$11.8Mraised▾
Series A · Cambridge, Massachusetts · founded 2019 · 10 employees
Developer of therapeutic drugs
Funding rounds
- Feb 2025Conventional Debt$6M
- Jul 2024Series A$1.8M
- Feb 2024Series A$4.1M
- Feb 2020Grant (prize money)—
Founders & team
Investors
CARB-X
#12
Series A · Amherst, Massachusetts · founded 2017 · 8 employees$6Mraised▾
Series A · Amherst, Massachusetts · founded 2017 · 8 employees
Enquyst Technologies is a biotechnology company that is revolutionizing the way biological drugs are manufactured. The company is developing novel, next-generation bioprocessing technology solutions to improve the efficiency and scalability of biologic production. Enquyst's patented technology is designed to simplify the downstream purification process, enabling the production of high-purity biologics at a lower cost.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 604 LinkedIn followers
Funding rounds
- Jun 2025Series A$6M
Investors
Eckuity
Funding & investor landscape
$2.4Btotal disclosed funding
54companies funded
193disclosed rounds
2rounds last 90 days
Most active investors
Atlas Venture3 rounds
Notable founders
Errik Anderson
CEO · Alloy Therapeutics
Ole Isacson
Co-Founder · Oryon
Nikola Kojic
Co-Founder & Chief Innovation Officer · Oryon
Kleem Chaudhary
President & Chief Executive Officer · Hyku Biosciences
Ajay Yekkirala
Co-Founder · Superluminal Medicines
Cony Dcruz
Co-Founder & CEO · Superluminal Medicines
Arthur Tzianabos
CEO · Lifordi
Ander Tallett
Co-Founder & COO · Dash Bio
Dave Johnson
Co-founder & CEO · Dash Bio
Gleb Kuznetsov
Co-Founder & CEO · Manifold Bio
Shane Lofgren
Co-Founder · Manifold Bio
William Lockwood-Benet
Co-Founder · Protein Dynamic Solutions
Prism market signals · United States · country-scoped Prism corpus, 1,368,075 docs
Market landscape — 10 sub-themes by coverage
Share of Biopharma Outsourcing coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH IN MASSACHUSETTS · Health & Bio
How research on Biotechnology in Massachusetts is moving
A read on the academic research around Biotechnology in Massachusetts — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 169 papers.
MGH, MIT, and UMass Chan lead Massachusetts biotech research, focusing optimistically on RNA interference, CRISPR, and gene delivery, with breakthroughs dominating over concerns.
169 papers · stance +0.51 · 51% breakthrough · 18% concern
top institutions
- Massachusetts General Hospital62
- Massachusetts Institute of Technology58
- University of Massachusetts Chan Medical School20
- University of Massachusetts Amherst18
- University of Massachusetts Boston7
leading researchers
David Julian McClements · Michael R. Hamblin · Ying‐Ying Huang · Aaron Chen · Allan S. Myerson · Alper James Alcaraz
prism intelligence · tone & topics
92% positive · 3% critical tone
PharmaceuticalsMedical ResearchHealthGeneticsClinical TrialsBiology
▲
Breakthroughs73 · 43%
▼ 50%→35% share
▼0.7× share momentum388 median citations40% since 2021mostly empirical
Messenger RNA breakthrough research is rising — papers tripled from 1 to 3 despite Breakthroughs segment shrinking from 50% to 35%.
rising sub-themes (early→recent)
- Messenger RNA1→3
- Transcription (linguistics)3→4
Landmark Comprehensive molecular profiling of lung adenocarcinoma · 5,754 cites
◆
Advancements44 · 26%
▲ 26%→28% share
▲1.1× share momentum1 median citations52% since 2021mostly empirical
In vivo research dominates Advancements at 10 papers as segment share grows from 26% to 28%.
rising sub-themes (early→recent)
- In vivo10
- Biodistribution3
- Cancer research2
- Apoptosis2
- Bacteria2
Landmark Fear Extinction as a Model for Translational Neuroscience: Ten Years of Progress · 1,441 cites
▼
Concerns25 · 15%
▲ 11%→16% share
▲1.5× share momentum2 median citations56% since 2021mostly reviews
Food industry and biochemical engineering concerns are intensifying — each reaching 3 papers as Concerns segment share surges from 11% to 16%.
rising sub-themes (early→recent)
- Food industry3
- Biochemical engineering3
- Food science2
- Glioma2
- Health benefits2
Landmark Genomic responses in mouse models poorly mimic human inflammatory diseases · 2,962 cites
Common questions
How many Biopharma Outsourcing companies are there in Massachusetts, United States?
Radar tracks 227 indexable Biopharma Outsourcing companies headquartered in Massachusetts, United States that meet our profile-completeness bar.
What is the total funding raised by Biopharma Outsourcing companies in Massachusetts, United States?
The Biopharma Outsourcing companies in Massachusetts, United States on this list have raised a combined $2.4B in disclosed equity funding across 54 funded companies.
Which is the highest-funded Biopharma Outsourcing company in Massachusetts, United States?
Biocytogen is the highest-funded Biopharma Outsourcing company in Massachusetts, United States, with $301.1M in disclosed equity funding.
How many Biopharma Outsourcing companies in Massachusetts, United States are funded?
54 of the 227 Biopharma Outsourcing companies in Massachusetts, United States on this list have disclosed at least one equity funding round.
How many Biopharma Outsourcing unicorns are there in Massachusetts, United States?
None of the Biopharma Outsourcing companies in Massachusetts, United States on this list currently has a disclosed valuation of $1B or more.
Who are the top investors in Massachusetts, United States Biopharma Outsourcing companies?
The most active investors in Massachusetts, United States Biopharma Outsourcing companies on this list include HHS, Massachusetts Biomedical Initiatives, Ampersand Capital, RA Capital Management, National Science Foundation.
Rohit KhannaTrends & Stories
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.